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Abstract
The accepted androgen receptor (AR) role is to promote proliferation and survival of prostate epithelium and thus prostate
cancer progression. While growth-inhibitory, tumor-suppressive AR effects have also been documented, the underlying
mechanisms are poorly understood. Here, we for the first time link AR anti-cancer action with cell senescence in vitro and in
vivo. First, AR-driven senescence was p53-independent. Instead, AR induced p21, which subsequently reduced DN isoform
of p63. Second, AR activation increased reactive oxygen species (ROS) and thereby suppressed Rb phosphorylation. Both
pathways were critical for senescence as was proven by p21 and Rb knock-down and by quenching ROS with N-Acetyl
cysteine and p63 silencing also mimicked AR-induced senescence. The two pathways engaged in a cross-talk, likely via PML
tumor suppressor, whose localization to senescence-associated chromatin foci was increased by AR activation. All these
pathways contributed to growth arrest, which resolved in senescence due to concomitant lack of p53 and high mTOR
activity. This is the first demonstration of senescence response caused by a nuclear hormone receptor.
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Introduction
Favorable response to androgen ablation, the mainstay prostate
cancer (PCa) treatment, is typically followed by a relapse to the
ablation-resistant disease [1]. Advanced PCa, while unresponsive to
anti-androgens often express functional androgen receptor (AR) [2].
In prostate stroma, low AR levels maintain the production of
andromedins, which initiate proliferation and differentiation of the
AR-negative basal epithelium [3]. AR expression increases as
prostate epithelium differentiates: it is absent in the stem and
transient amplifying basal cells and high in secretory luminal
epithelium where it functions to suppress proliferation and maintain
terminal differentiation [4]. AR oncogenic action has been
extensively studied: in tumor cells AR activation can cause
proliferation and block apoptosis [5], suggesting that altered context
enables AR to support cell growth [6]. AR proliferative effects rely
on Cyclin D1 [7]; its survival effects involve Akt and anti-apoptotic
proteins Bcl-2 and Mcl [8]. AR also stimulates the expression of
autocrine growth factors via O2-independent stabilization of HIF-1
[9]; other evidence underscores AR non-genomic oncogenic action
via cholesterol-rich membrane microdomains [8,10].
There are several significant observations that are inconsistent
with AR oncogenic function in the prostate epithelium. Trans-
genic mice overexpressing wild-type AR in the prostate epithelium
fail to develop PCa [11], whereas mutations in the N-terminal
motif ARNSM alter AR interaction with co-factors and enable
oncogenic functions [12]. Moreover, the evidence of AR anti-
proliferative and anti-tumor effects in the prostate emerges
continuously. AR sensitizes PCa cells to apoptosis by cytotoxic
drugs, induces apoptosis in cooperation with Rb [13,14] and
suppresses metastasis-promoting factors c-Met and VEGF-C
[15,16]. Recently, AR has been identified as a replication licensing
factor, which has to be degraded for continuous cell cycling [6].
Re-introduction and/or activation of AR halt PCa growth in vivo
[17,18]. Moreover, clinical observations indicate that prostate
tumors progress slower in patients treated with an intermittent
androgen blockade alternated with testosterone replacement, than
in patients on continuous androgen ablation [19,20]. Thus
androgen axis may be beneficial in averting PCa. Our group
showed that in AR-null PC-3 cells inducible AR expression causes
androgen-dependent tumor suppression, accompanied by de-
creased angiogenesis [17].
Here we demonstrate that continuous AR activation in vitro and
in vivo cause cellular senescence, which can be attenuated by AR
antagonist, anti-androgen flutamide. Cellular senescence is one of
the events underlying tumor suppression. Senescence can be
triggered by telomere shortening or stress, including inappropriate
expression of growth-promoting genes, GTPases or reactive
oxygen species (ROS) [21]. Senescence can be driven by Rb or
p53 pathways, which are closely intertwined: Rb can block p53-
destabilizing protein MDM2, thus increase p53 levels, promoting
the expression of p53 targets, p21, Bax and PIG3 and cause
senescence [22,23]. On the other hand, p21 inhibits cyclin
dependent kinases (Cdks) and therefore dephosphorylates and
activates Rb, which then binds E2F allowing the expression of
growth arrest genes and senescence [22,24].
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senescence. Transcriptionally active p63 isoform, TAp63, can
induce apoptosis by activating p53 targets genes; however its
inactive, short isoform DNp63 can block p53 and TAp63 function
in a dominant-negative fashion [25]. Despite well documented
pro-apoptotic activity of TAp63, p63-null animals showed
impaired tumorigenesis compared to the wild-type littermates.
Importantly, p63 inactivation targeted to the prostate epithelium
causes premature senescence and lowers tumor incidence [26].
Importantly, the patterns of AR and p63 expression in
differentiating prostate epithelium are reciprocal [27]. While basal
epithelial cells express no AR and high levels of DNp63,
differentiated luminal secretory epithelium expresses highest AR
levels and no p63 [27]. P63 deficiency can release the expression of
known senescence-associated proteins p21, p53, Rb, and PML
(promyelocytic leukemia) tumor suppressor [26].
In our model, AR-induced senescence occurred independently
of DNA damage and p53. Instead, it involved increased p21 levels,
decreased phospho-Rb and p63. Additionally, we observed
increased numbers of PML nuclear bodies due to AR-dependent
p63 depletion. P21 expression was directly regulated by AR, as
was shown by chromatin immunoprecipitation (ChIP). Paradox-
ically, p21 had no effect on Rb phosphorylation: the decrease of
the phospho-Rb was due to AR-dependent ROS increase.
Elevated P21, on the other hand, caused depletion of the
DNp63. AR-dependent senescence was blocked by p21 or Rb
silencing, as well as by ROS quenching and vice versa, mimicked
by p63 knockdown. Thus we identified a novel AR function, the
induction of senescence, previously not ascribed to any of the
nuclear hormone receptors, and delineated underlying signaling
pathways.
Results
Persistent AR activity causes senescence
To avoid the loss of androgen sensitivity due to persistent AR
expression/activity we generated PC-3 PCa cells expressing
tetracycline-inducible wild-type AR (PC3-AR) [17] (Fig. 1A). We
showed that persistent (up to 6 days) AR activation did not
increase cell numbers, judging by WST-1 viability assay or direct
cell counts (Fig. 1B and data not shown). On the contrary, long-
term AR activation resulted in G1 growth arrest (Fig. 1C), which
was not accompanied by cell death (Fig. S1A); however, the cells
assumed flattened vacuolized morphology, suggestive of either
autophagy or senescence (Fig. S1B). The levels of the principal
autophagy mediator Beclin-1 [23,28] remained stable in the
presence of DHT (Fig. 1C) pointing to senescence. Moreover, SA-
bGal positivity increased from the background 4% to nearly 40%
in the presence of DHT (P,0.0002), suggesting senescence. This
increase was abolished by anti-androgen flutamide (Fig. 1D–E,
P,0.005).
In AR-positive LNCaP PCa cells persistent AR activation
caused similar phenotype (Fig. 1D–E). Other studies demonstrated
AR-dependent growth arrest in LNCaP cells [29]. To assess AR
effect in the normal prostate epithelium, we introduced AR into
normal immortal prostate epithelial cell line, RWPE-1 using
lentiviral vector (Fig. 1F). Parental RWPE-1 express no detectable
AR and high levels of p63 and other markers of transiently
amplifying basal epithelium [30]. Prolonged (3–5 days) DHT
exposure significantly increased senescence albeit it remained
considerably lower than in PCa cells (7–12%, Fig. 1G–I). After 3–
6 days of DHT exposure, senescent PC3-AR cells failed to resume
growth when transferred in DHT-free medium as was evidenced
by persistence of bGAL-positive cells (Fig. S1F), suggesting that
growth arrest was permanent. Together, our findings indicate that
ligand-dependent AR activity induced senescence in PCa and
normal basal prostate epithelial cells.
We then proceeded to verify the possibility of AR-induced
senescence in vivo. One possible in vivo experiment, the treatment
of male animals with ectopic testosterone, involves testosterone
concentrations exceeding physiological levels. The detection of
senescence in normal prostate on ambient testosterone back-
ground would not unequivocally link senescence to AR and
testosterone, since in the only possible control (castration or
testosterone depletion) causes apoptosis and rapid involution of the
gland, which preclude the detection of senescence. As was
reported previously, inducible (tet-on) AR expression inhibits the
growth of PC3-AR tumors on ambient testosterone background in
male mice [17] and this inhibition is reversed by flutamide
(Fig. 2A–B, and Fig. 2A–B). SA-bGal assay revealed increased
senescence in PC3-AR tumors treated with Dox (Fig. 2C).
Similarly, ectopic DHT impaired the progression of AR-positive
LNCaP tumors on testosterone-free background, with concomi-
tant increase in SA-bGal positivity (Fig. S2C–E).
Persistent AR activation did not incur DNA damage
We observed no decrease in telomerase activity or telomere
following DHT treatment (Fig. S3A–B), thus ruling out replicative
senescence. Senescence can also occur through DNA damage
response (DDR) caused by oncogenic stress [22,31] and AR
possesses oncogenic functions, we sought DNA damage as possible
cause for senescence [31]. However, in PC3-AR and RWPE-AR
cells staining for phospho-histone cH2-AX revealed no significant
change in the number of cH2-AX foci per nucleus following 24,
48 and 72 hour DHT exposure (Fig. S3C–D).
AR upregulated p21 and decreased Rb phosphorylation
We examined AR effect on known mediators of growth arrest
and senescence. PC-3 cells are p53 and p16 null (ATCC and Fig.
S4A); RWPE-1 cells are p53 and Rb null [32]. LNCaP cells
express wild-type p53, but its levels were unchanged by DHT
exposure (Fig. S4B). Collectively, these data suggest that p53 is
dispensable for AR-induced senescence. In PC3-AR and LNCaP
treated with DHT, Rb phosphorylation visibly diminished (Fig. 3A
and Fig. S4C). Cyclin D1 levels also decreased, but the regulation
pattern was distinct from Rb; on days 5–7 Cyclin D1 expression
returned to control levels, while the decline in phospho-Rb
persisted (Fig. S4D). P21 levels rose after 24 hour DHT exposure
in PC3- and RWPE-AR cells and persisted at least seven days
(Fig. 3A–B and Fig. S4C). In contrast, pro-survival Bcl2 declined
on day 3 and remained low thereafter (Fig. S4E). These changes
were dependent on AR transcriptional activity since they were
reversed by flutamide (Fig. 3A and Fig. S4C).
P21 was critical for AR-induced senescence but not for
the lower Rb phosphorylation
Previous studies demonstrated that AR increased p21 promoter
activity and identified putative ARE [33]; however, direct AR
binding to p21 promoter has not been shown. Using ChIP we
showed AR association with p21 promoter fragment adjacent to
the putative ARE (Fig. 3C) suggesting direct p21 transactivation. A
Cdk inhibitor, p21 can repress Rb phosphorylation [34,35,36].
However, in PC3-AR, p21 silencing failed to ameliorate the
decrease in Rb phosphorylation in the presence of DHT (Fig. 3D).
Nevertheless, p21 was critical for AR-induced senescence since
p21 silencing significantly reduced SA-bGal-positive population
after DHT-treatment cells (Fig. 3E–F; P,0.003).
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PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e31052Figure 1. AR activation causes cell cycle arrest and senescence in PC3 cells. AR activation causes cell cycle arrest and senescence in PC3
cells. (A) In situ immunofluorescence with anti-AR antibody: note diffuse AR staining in control treated PC3-AR cells (left) and nuclear translocation on
3 day of DHT treatment (right). (B) Time-dependent inhibition of cell growth in vitro. PC-3 cells were cultured in Dox 6 DHT; viable cells were
measured using WST-1 reagent. Each time point represents mean 6 standard deviation of three independent experiments. The difference between
DHT treatment (red) and control EtOH (green) is statistically significant on day 5 (P,0.01). (C) Cell cycle analysis: the cells were grown in Dox, in the
absence (D) and in the presence of DHT (DD) for 3 and 5 days; after 7 days the cells were passed (P1) and incubated for another 5 days. Cell cycle
distribution was analyzed by flow cytometry. Note increased cell number in Go/G1 phase accompanied by decreased in S and G2/M populations in
DHT-treated cells (DD) compared to Dox alone (D). (D) PC3-AR cells were cultured in Dox and treated with DHT 6 Flutamide (Fl, 20 mM). After five
days senescence was measured using SA-bGal assay. Note increased bGal positivity upon AR activation and the lack of senescence in the presence of
Fl. (E) Senescent cells were counted on the digital images of 5 random fields using Image Tool 3.00 software (UTHSCSA); means of three independent
experiments with S.D.M. are shown. (F) RWPE-1 cells were transfected with control lentivirus or lentiviral vector encoding AR. AR expression was
measured in whole cell lysates by Western blot. GAPDH antibody was used to assess loading. (G, H) RWPE-AR and vector transfected (RWPE-C) cells
were cultured in DHT, DHT and Flutamide (Fl) or with equal volume of EtOH added as control. Senescence was assessed with SA-bGal assay (I) and
quantified as in (E).
doi:10.1371/journal.pone.0031052.g001
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ROS
AR activation can increase reactive oxygen species (ROS) in
LNCaP cells [37]. On the other hand, ROS was implicated in Rb-
mediated senescence [21]. In PC3-AR cells, AR activation visibly
increased ROS (Fig. 4A) and this increase significantly contributed
to AR-induced senescence whereas N-acetyl cysteine (NAC)
reduced AR-mediated senescence (Fig. 4B–C). In agreement,
NAC attenuated AR-dependent reduction in phospho-Rb
(Fig. 4D). Rb, in turn, was critical since siRNA knock-down
(Fig. 4E) lowered senescence in the presence of DHT by ,80%
(P,0.00006) (Fig. 4F, G). Although others identified p16 as a
mediator of ROS dependent Rb activation [21], we failed to
detect p16 in PC3-AR cells (Fig. S4A), which implied alternative
means of ROS induction.
AR reduced p63 expression via p21
P63, a member of p53 family, is a marker of AR-negative
prostate stem cells and transiently amplifying basal prostate
epithelium; it is also expressed by less differentiated, more
aggressive PCa [27,38]. In contrast, p63 deficit is implicated in
senescence [39]. Since p63 is not detected in AR-positive luminal
prostate epithelium, we hypothesized that AR may block p63
expression. TAp63-a and DNp63 were expressed in PC3-AR and
RWPE-AR in the absence of DHT and noticeably decreased
DNp63 after DHT treatment (Fig. 5A–B). This decrease was
reversed by flutamide suggesting AR genomic action (Fig. 5A and
data not shown). The regulation also occurred at mRNA level: in
PC3-AR cells after 48–72 hours with DHT p63 mRNA declined
by 85% (Fig. 5C). Interestingly, p21 knock-down increased p63
protein and mRNA (Fig. 5A, C). Although the repression by DHT
was partially retained in p21 knock-down cells, p63 message
remained at least 5-fold higher in DHT-treated p21-null cells,
similar to untreated control PC3-AR. AR activation also caused
p63 exclusion from the nuclei (Fig. 5D), suggesting that nuclear
DNp63 is important for blocking senescence. Further, down-
regulation of p63 protein by DHT was lost in p21 knock-down
cells (Fig. 5A, E). P63 deficit likely contributed to the AR-driven
senescence, since p63 knock-down elevated senescence in parental
PC-3 cells (Fig. 5F and G).
AR-dependent p63 deficit increases PML expression
One possible p63 target involved in senescence is PML tumor
suppressor whose link to senescence is well documented [40]. PML
levels are dramatically higher in the cells cultured from p63 null
mice [26]. In PC3-AR cells DHT treatment caused increase in the
number of PML bodies per nucleus. This number significantly
increased after 5 days and was reversed by flutamide (Fig. 6A, C,
E). The average diameter of the PML bodies remained the same
(1.860.8 mm in control and 260.3 mm in DHT-treated cells,
P=0.065). Furthermore, the number of PML bodies per cell was
increased upon p63 knock-down (Fig. 6B, C), and reduced by p21
silencing (Fig. 6D). Interestingly, in PC3-AR cells DHT treatment
and p63 knock-down showed increased nuclear staining for Rb
(Fig. 6B and E).
mTOR activity in AR-positive cells remained high
Growth arrest may be resolved via quiescence or senescence
and the choice is dictated by mTOR activity. In the absence of
p53, low mTOR activity allows cells to remain quiescent while
high mTOR activity promotes senescence [41,42,43,44]. In p53-
negative PC3-AR cells AR activationdid not significantly alter
mTOR activity remained high as was evidenced by phosphpryla-
tion levels (Fig. 7A). Phosphorylation of mTOR target, p70S6
kinase also remained high (not shown). We therefore conclude that
Rb activation, increased p21, and decreased DNp63 together
caused cell cycle arrest and senescence, with high mTOR activity,
in the absence of p53 (Fig. 7B).
AR-dependent senescence is associated with reduced
cytokine expression
Stress-induced senescence can cause cytokine release recipro-
cated by the host inflammatory response, which has tumor
promoting effect [45]. To examine this possibility, we used
multiplex antibody array for 16 inflammatory cytokines and
chemokines. AR significantly altered the levels of at least seven
Figure 2. AR-dependent tumor suppression was associated with increased cellular senescence. AR increased cellular senescence in vivo.
(A) Experimental design. Male athymic mice (nu/nu, 5 mice/group) were injected s.c. with vector control (PC3-V) or PC3-AR cells and received Dox
with drinking water, where indicated, to induce AR expression. Flutamide was given to counteract endogenous testosterone. (B) Mean tumor
volumes and standard deviations are shown at 45-day time point. Note lower volume of PC3-AR tumors in male mice treated with Dox, and the lack
of the decrease when Fl was added to the treatment. (C) Sections of frozen tumors collected in the experiments above were subjected to SA-bGal
assay to detect senescence. Note increased bGal positivity (blue) in PC3-AR tumors treated with Dox and of LNCaP tumors treated with DHT.
doi:10.1371/journal.pone.0031052.g002
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Eotaxin and I-809) (Fig. S5). Surprisingly, with the exception of
eotaxin most other factors were decreased after 3 and 5 days of
DHT exposure and this decrease was reversed by flutamide. This
data suggests a decreased inflammatory potential of the AR-
positive tumors.
Discussion
We have shown that persistent AR activity promotes cellular
senescence in prostate cancer and in normal prostate epithelial
cells. Senescence is recognized as a tumor-suppressive event
whereas the proportion of senescent cells is high in pre-cancerous
lesions and falls in the course of malignant progression [46] and
the failure to undergo senescence is one of the properties which
makes cancer stem cells therapy-resistant [47]. In agreement, our
study indicates that AR-driven senescence is associated with
reduced tumorigenesis.
Unaltered telomerase activity suggested that AR activation
caused either DNA damage- (DDR) or stress-induced (SIS), rather
than replicative senescence. The involvement of Ras in AR-
dependent cellular senescence was unlikely, since Ras expression
and activity are constitutively high in PaCa cells regardless of AR
status [48,49]. Both DDR and SIS can be caused via p14/Arf -
p53, or p16/INK - Rb pathways. However, the numbers of cH2-
AX positive foci indicative of DNA damage remained similar in
DHT-treated and control cells ruling DDR out.
DDR and SIS can cross-communicate via p53 downstream
target, p21, an inhibitor of Cdks, or via MDM2 downregulation
downstream of Rb, which increases p53 stability [23]. However,
AR-positive derivatives of PC-3 and RWPE-1 cells are p53 null.
Interestingly, p53 levels remained unaltered after AR activation in
LNCaP cells in the presence of DHT suggesting that p53 is non-
essential for AR-driven senescence.
G1 arrest after 3-day DHT exposure was followed by a
significant increase in senescence at day 5 and thereafter and
senescence increased after the passage of the surviving cell
population or the transfer to androgen-free environment, further
supporting senescence and not temporary growth arrest (quies-
cence). At the same time, PC3-AR cells remained resistant to
Figure 3. p21 is regulated by AR and required for cellular senescence. AR-dependent senescence required increased p21. (A) PC3-AR cells
were treated with Dox, DHT and Fl, at indicated combinations; cell extracts were analyzed by Western blot for p21, and ppRb. Tubulin was used as a
loading control (A). Note the decrease in Rb phosphorylation and p21 increase in DHT-treated cells at every time point. (B) RWPE-1 cells, non-
transfected or transfected with pLVX-AR or pLVX vector were treated with vehicle EtOH and DHT with or without Fl. Cell extracts were analyzed for
AR, p21 and GAPDH to assess loading. (C) AR binding to p21 promoter: ChIP was performed with AR antibodies and AR-bound DNA amplified with
the primers for the promoter region adjacent to the putative ARE element within p21 promoter (top) using real-time PCR. Each sample was run in
triplicates, normalized per input DNA, and fold change in occupancy was calculated as FC=2
(2DDCT [exp-con]). Note increased AR binding to the p21
promoter in the presence of DHT and the reversal by flutamide (Fl, concentration shown in mM). The results of three independent experiments are
pulled together (P,0.04). (D) PC3-AR cells were transfected with p21 or non-target control siRNA. Cell extracts were collected after 48 hours and
analyzed by Western blot for p21, phospho-Rb (ppRb) and tubulin (loading control). Untransfected cells (-) are shown for comparison. (E, F) The
transfectants were allowed 48 hours to recover and treated 5 days with Dox, DHT and Fl, as indicated; senescence was measured by SA-bGal assay.
Note a significantly lower senescence levels after p21 knock-down (F, P,0.006). SA-bGal positive cells were quantified as above. Means and S.D. were
calculated for three independent experiments. Representative images are shown (F).
doi:10.1371/journal.pone.0031052.g003
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likely due to lacking p53. Seeking molecular mechanisms of AR-
dependent growth arrest, we identified p21 as direct AR
transcriptional target. On the other hand, we detected striking
reduction of phospho-Rb downstream of AR, which, to our
surprise, was not obliterated by p21 knock-down. Moreover, the
pattern of Cyclin D1 decrease over time bore no direct correlation
with p21 or Rb. On the other hand, AR activation enhanced ROS
accumulation, which appeared critical for Rb dephosphorylation
as was shown by ROS quenching. Increased ROS levels may be
caused by the elevated PKCd expression downstream of AR,
which was documented previously [21,50] or by AR-dependent
Bcl2 decrease [51]. Oncogene activation and subsequent ROS
increase have been linked to the p16/INK, Rb and senescence
[21]. However, PC-3 and RWPE-1 cells express no detectable
p16. In some systems p21 also causes increased ROS and
senescence [52]. However, obvious lack of causal link between p21
and AR-dependent Rb phosphorylation suggests that AR-induced
ROS triggers Rb activation independent of p53, p21, and p16/
INK. Other possibilities include ROS-dependent activation of the
p27 Cdk inhibitor or PP2A, which can directly dephosphorylate
Rb downstream of ROS [53].
TA-p63 and DNp63 were expressed in PC3-AR and RWPE-1
cells and DNp63 significantly downregulated upon AR activation.
A member of p53 family p63 has been linked to senescence,
although its mechanisms are not completely understood. The role
of p63 PCa is complex; while in most cases PCa tissues stain
negative for p63 [54], the more aggressive tumors are thought to
originate from p63-positive basal epithelial cells [55,56]. In
prostate, stem cells and basal epithelium express DNp63 [57],
and decrease of the DN isoform allows differentiation and possibly
senescence. In agreement, study of mice, with isoform-specific p63
knock-down shows that DNp63 plays a key role in maintaining
stem cell renewal and longevity [58]. P63 deficit can cause
premature senescence by permitting release of the p19
Arf (p14
Arf in
humans) to the nucleoplasm and subsequent p53 activation [59],
by releasing p16/INK expression followed by Rb activation [26]
and finally, via promyelocytic leukemia (PML) tumor suppressor
[26]. Concomitant with marked decrease in p63 due to persistent
AR activity, we found more PML bodies in the nuclei of PC3-AR
cells in the presence of DHT and in parental PC-3 cells after p63
knock-down. In contrast, p21 knock-down in PC3-AR elevated
DNp63 and abolished the increase of PML body numbers.
Interestingly, in prostate epithelium p63 is the marker of stem and
transient amplifying basal cells such as RWPE-1. P63 expression
decreases along with capacity for self-renewal and completely
ceases in terminally differentiated secretory luminal cells [27].
Thus AR induction in PCa cells likely re-activates differentiation
program, which may ultimately augments stress-induced senes-
cence; this conclusion is corroborated by our previous finding,
whereas cytokeratin 8 levels increased upon AR activation [17]. In
agreement with our data, targeted AR inactivation in the prostate
epithelium causes increased proliferation and blocks differentiation
[60].
The fact that AR induces senescence at a much lower rate in
RWPE-1 cells lacking both p53 and Rb, compared to Rb-positive
PC-3 cells suggest that AR activation triggers parallel pathways,
which both contribute to senescence and may be engaged in a
cross-talk (Fig. 6F). In one pathway, AR enhances ROS
production by PCa cells thus reducing Rb phosphorylation, so
that active Rb binds and sequesters E2F, thus causing cell cycle
arrest (Fig. 6F, left). On the other hand, AR directly binds p21
promoter and thus causes accumulation of p21, which attenuates,
via unknown mechanism, the expression of p63 and therefore
Figure 4. AR-induced senescence requires ROS and Rb. This
figure depicts the role of ROS and RB in AR-dependent senescence. (A).
PC3-AR cells were treated with Dox, DHT and Fl, as indicated and ROS
assessed by DHE fluorescence. Note increased ROS upon DHT treatment
and lower DHE fluorescence in the presence of Fl (20 mM). ROS
quencher, NAC (10 mM) was used as a negative control. (B, C) The
effect of NAC on AR-induced senescence: PC3-AR cells were cultured in
Dox, AR activated with DHT 6 NAC, and senescent cells visualized with
SA-bGal assay. Representative images (B) and quantitative assessment
(C) are shown. (D) PC3-AR cells were cultured in Dox, treated 24 hours
with DHT and/or NAC (20 mM) where indicated. Cell extracts were
analyzed by western blot for phospho-Rb. PCNA was used to assess
loading. Note increased Rb phosphorylation in the presence of NAC. (E)
PC3-AR cells were transfected with Rb siRNA and Rb levels measured
after 24 hours by western blot. Note ,2-fold reduction after
transfection with Rb siRNA. (F, G) Senescence was measured by SA-
bGal assay on day 6 after Rb knock-down (values calculated as in Fig. 1,
S.D. values are shown; P,0.0002). Note the reduced senescence of the
DHT-treated cells after Rb knock-down. Representative images are
shown below (G).
doi:10.1371/journal.pone.0031052.g004
Androgen Receptor Drives Senescence
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e31052increases the number of the PML nuclear bodies (Fig. 6F, right).
Elevated p21 levels may additionally decrease in phospho-Rb by
blocking Cdks. Furthermore, transcriptionally inactive Rb/E2F/
HDAC complexes could be docked to PML bodies [61] and
thereby maintain quiescence. The lower levels of AR-induced
senescence in RWPE-1 cells suggest the predominant role of Rb
over p63 depletion.
In cells that like PC-3 are p53-deficient, senescence mTOR
promotes senescence [44,62,63]. We found mTOR constitutively
active in PC-3 cells regardless of AR induction. Apparently,
increased Rb and p21 signaling along with DNp63 depletion by
AR cause the state of quiescence PCa cells. Lack of p53 allows
mTOR -driven senescence, which, in turn, opposes tumor
progression.
AR induction of cellular senescence may be interpreted as a
tumor suppressive action, or as inappropriate oncogene activation,
similar to Ras and Myc [24,31]. Direct up-regulation of p21 and
repression of the DNp63 associated with stemness imply tumor
suppressive activity. Recent study shows that approximately 50%
of AR mutations induced by androgen ablation reduce or abolish
its transactivation activity [64], also suggesting tumor suppressive
function. In addition to its direct tumor suppressive effect,
senescence may increase the production of inflammatory cytokines
and thus promote the growth and proliferation of a non-senescent
cell population in a tumor, a phenomenon termed senescence-
associated secretory phenotype (SASP) [65]. However, multiplex
analysis of the cytokine production by the PCa cells after 3 and 5
day of AR activation revealed significant decrease in at least seven
major growth and inflammatory factors, suggesting that AR-
dependent senescence does not incur SASP and associated tumor-
promoting effects.
In conclusion, our study clearly demonstrates that there is more
than one side to AR activation: the canonical pro-proliferative,
oncogenic AR activity is counterbalanced by its less studied
Figure 5. p63 expression is blocked by P21 and contributes to AR-dependent senescence. This figure illustrates the link between p21 and
p63 n AR-driven senescence. (A) PC3-AR cells were transfected with non-target (NT), p21 or p63 siRNA. Dox 6 DHT were added to the media
24 hours post-transfection. Whole cell lysates were collected after 3 days and p63 expression measured by Western blot. Arrows point to TAp63-a
and DNp63; * indicates non-specific band. Note the lack of p63 downregulation in p21 knock-down cells. (B) RWPE-1 cells were transfected with
pLVX-AR or control pLVX and treated with vehicle EtOH or DHT. TAp63-a and DNp63 were measured as in (A). (C) PC3-AR cells were transfected with
p21 or non-target (NT) siRNA. The cells were placed in Dox, 6 DHT. RNA was isolated 3 days post-transfection. P63 message was measured by real-
time RT-PCR. Note an approximately seven-fold reduction upon DHT treatment and increased expression after p21 knock-down. (D) In situ
immunofluorescence of PC3-AR cells with pan-p63 antibody. Note pronounced p63 nuclear staining in Dox-treated cells, the lack of nuclear staining
after 3 days in DHT and restored nuclear staining in the presence of Fl (top). Below: P63 nuclear localization (green pseudocolor), nuclei are
counterstained with DAPI (red pseudocolor); colocalization appears in yellow. (E) PC3-AR cells were transfected with p21, p63 or control siRNA,
cultured 48 hours in Dox 6 DHT and stained with p63 antibodies. Note similar, diffuse p63 localization with the nuclear presence (filled arrows) in
Dox-treated cells, the lack of nuclear localization in the presence of DHT (empty arrows), which is lost after p21 knock-down (filled arrows). P63 knock-
down results in a weak, residual cytoplasmic staining. (F, G) Parental PC3 cells lacking AR expression were transfected with NT and p63 siRNA,
cultured 5 days and senescence measured by SA-bGal assay. Representative images (left) and quantitative analysis (right) are shown. * indicates
P,0.05.
doi:10.1371/journal.pone.0031052.g005
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Our observations may explain why initial robust clinical response
to androgen ablation is frequently followed by emergence of a
more aggressive hormone-independent PCa.
Materials and Methods
Cells
PC3cells induciblyexpressing wild-typeAR (PC3-AR) havebeen
established previously [17]. PC3-AR cells were routinely main-
tained in RPMI, 2% pen/strep, 1 mg/ml blasticidine, 50 mg/ml
zeocine (VWR, West Chester, PA), 10% tetracycline-free serum
(HyClone, Logan, UT). For the experiments, the cells were allowed
to adhere 24 hrs and incubated overnight in starvation media with
0.2% FBS. AR induction with 1 mg/ml doxycyclin (Dox, Fluka, St.
Louis, MO) was carried out in phenol-free RPMI, antibiotics and
10% charcoal-stripped serum (HyClone), with or without 1 nM
synthetic androgen (R1881, thereafter referred to as DHT, Sigma,
St. Louis, MO ); the media was replaced every 48 hrs. LNCaP cells
(ATCC) were cultured in RPMI, with charcoal-stripped serum.
Immortalized normal prostate epithelial cells RWPE-1 (ATCC)
weregrowninkeratinocyteserumfreeK-SFMmediasupplemented
with bovine pituitary extract and EGF (Invitrogen, Carlsbad, CA).
AR induction was performed as above.
Figure 6. AR alters PML aggregation via p63 pathway. PML tumor suppressor was linked to AR dependent senescence. (A, C) PC3-AR cells
were cultured in Dox (D) and treated with DHT (DD) or DHT and Fl (DDF) for 48 hours and stained for AR, to assess activation state, and for PML (A).
The number of PML bodies per 206field was measured using MetaMorph software and recalculated per single cell (C, left). Note a significant increase
in the number of PML bodies/cell in the presence of DHT (P,0.02), but not in the presence of Fl. (B, C) PC3-AR cells were transfected with NT or p63
siRNA, cultured for 3 and 5 days and stained for PML and Rb. The number of PML bodies per cell was calculated as above (C, right). Note a robust
decrease in PML staining upon p63 knock-down (day 3, P,0.05; day 5, P,0.0001). (D) PC3-AR cells were transfected with non-target (NT) or p21
siRNA, treated for 3 days with DHT and stained for PML. Note decreased staining upon p21 knock-down. (E) PC3-AR treated 3 days with Dox 6 DHT
and stained for AR, Rb and PML. Note AR activation and nuclear translocation, concomitantly increased intensity of Rb staining with appearance of
partial aggregation, and co-localization of Rb aggregates with PML nuclear bodies.
doi:10.1371/journal.pone.0031052.g006
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PC3-AR cells were injected s.c. in the hindquarters of athymic
male mice (nu/nu, National Cancer Institute, 4–6 weeks), 10
6 cells/
site, 5 animals/group, 2 sites/animal. To induce AR expression,
Dox (1 mg/ml) was given in drinking water. The tumors were
measured every 3 days; the volumes were calculated as
length6width
260.52. Flutamide (40 mg/kg/day, Sigma) was
given in drinking water. LNCaP cells were inoculated into the
flanks of the same numbers of female athymic mice; the mice
simultaneously received s.c implants of DHT or mock control
pellets (generated in the lab as previously described [17]). At the
endpoint, tumors were removed and snap-frozen. The animals
were handled according to the National Institute of Health
guidelines, the protocols approved by Northwestern University
Animal Care and Use Committee.
Cell growth assay
Cells were seeded in the 96-well plates and treated with DHT
for 7 days. Viable cells were quantified at day 1, 2, 5 and 6, using
WST-1 reagent (Clontech, Mountain View, CA). Absorbance was
measured in the microplate reader (BioRad, Hercules, CA).
Cell cycle analysis
Cells were collected by trypsinization, washed 2 times in wash
buffer (PBS, 0.1%NaN3, 1% FBS) and fixed overnight (75%
ethanol, 220uC). Fixed cells were rinsed in wash buffer with
0.25% Triton-X100, re-suspended in wash buffer with FITC-
conjugated Cyclin B1 monoclonal antibody (pre-diluted, 20 ml/
10
6 cells in 100 ml buffer) and incubated 1 hr (RT). The cells were
washed, re-suspended in 0.5 ml propidium iodide solution (10 mg/
ml PI, 1 mg/ml RNase A, 30 min at 37uC) and analyzed by flow
cytometry (ModFit software). FITC-conjugated mouse IgG (BD
Biosciences, San Jose, CA) served as a negative control.
SA-b-Gal assay
Cells grown on coverslips in 24-well plates were treated as
indicated, briefly washed with PBS, fixed in 2% paraformalde-
hyde, 0.25% glutaraldehyde (10 min, RT) and rinsed several times
in PBS. The coverslips were incubated overnight at 37uCi n
staining solution [66], washed in PBS and counterstained with
Nuclear Red. Coverslips were dehydrated in ethanol, cleared with
xylene and mounted (Permount, Science Company, Denver, CO).
Western blot analysis
Total cell lysates were prepared in RIPA buffer (1% NP-40,
0.1%SDS, 0.5% sodium deoxycholate, in PBS); cytoplasmic and
nuclear extracts were prepared using CNM compartment protein
extraction kit (Biochain Inst., Hayward, CA). Protein extracts (20–
50 mg/sample) were separated on 4–20% gradient PAAG,
transferred to PVDF membranes and probed with appropriate
primary antibodies (Table S1) following manufacturer’s instruc-
tions. Membranes were blocked with TBS-T (5% dry milk; 5%
BSA for phospho-specific antibodies). Secondary antibodies (HRP-
conjugated goat anti-rabbit, or goat anti-mouse IgG (Fab9)2,
1:20000 and 1:10000 dilution, respectively) were added at RT for
45 min in 5% milk/TBS-T. Bands were visualized with chemi-
luminescent substrate (GE Healthcare, Piscataway, NJ). Tubulin
or GAPDH served as loading controls for the total and
cytoplasmic extracts; TATA binding protein (TBP) was used for
the nuclear extracts.
siRNA transfection
siRNA (p21, p63, Rb) and scrambled siRNA controls were from
Dharmacon, (Lafayette, CO). The cells were seeded in six-well
plates (3610
5/well) 24 hrs before transfection in antibiotic-free
growth media. siRNA were diluted in 200 ml serum-free media to
final 100 nM. DharmaFECT reagent was diluted 1:50 in serum-
free medium, mixed 1:1 with diluted siRNA, incubated for 20 min
at RT and added to the cells (400 ml per well) for 24 hrs.
AR cloning
Human AR cDNA (Open Biosystems, Huntsville, AL) was PCR-
amplified (59-GCTCGAGAGGATGGAAGTGCAGTTAGG and
59-CGGATCCGCTTCACTGGGTGTGGAAATAGATG prim-
ers) ligated into Xho I/Bam H I sites of a bicistronic lentiviral vector
pLVX-IRES-ZsGreen1 (Clontech, Mountain View, CA).
Figure 7. Molecular mechanism of the AR-induced senescence. This figure summarizes our findings. (A) mTOR activity in PC3-AR cells. Cells
were treated with Dox alone (D) or in combination with DHT. Cell extracts were collected at days 3 and 5 of treatment and analyzed by Western blot
for phosphorylated mTOR and p70S6K. Tubulin and total p70S6K served as loading controls. (B) Schematic representation of pathways leading to AR-
indiced senescence: AR triggers two parallel pathways, necessary to ensure senescence and possibly engaged in a cross-talk: (1) Activated AR directly
binds p21 promoter and thus causes protein expression and accumulation. P21 attenuates the levels of TAp63-a, increasing the number of PML
nuclear bodies and causing senescence (2) AR enhances ROS production thus reducing phospho-Rb levels, while active Rb binds and sequesters E2F,
causing senescence. Elevated p21 levels may additionally decrease phospho-Rb by blocking Cdks. Conversely, transcriptionally inactive Rb/E2F/HDAC
complexes may be sequestered in PML bodies to maintain irreversible growth arrest/senescence. These pathways cumulatively contribute to
quiescence, which progresses to senescence due to constitutive high mTOR activity.
doi:10.1371/journal.pone.0031052.g007
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HEK-293T cells were transfected using Lentiphos HT reagent
(Clontech, Mountain View, CA) with lentiviral vector plasmid
(pLVX-AR or pLVX control) and packaging plasmids pPAX2 and
pMD2.G. After overnight exposure, the transfection media was
replaced with complete growth medium and the incubation
continued for 48 h. Viral supernatants were harvested and
concentrated using Lenti-X concentrator (Clontech, Mountain
View, CA). To determine titers, concentrated supernatant was
serially diluted and transfected into HEK 293T cells in a 24-well
cell plate and efficiency determined by ZsGreen fluorescence.
RWPE-1 cells were transduced with pLVX-AR or pLVX lentiviral
particles at MOI 10. Transduced cells were visualized by epi-
fluorescent microscopy and enriched by FACS. AR expression was
verified by Western blotting.
Real-time RT-PCR
Total RNA was extracted using GeneElute extraction kit
(Sigma, St. Louis, MO) following the manufacturer’s protocol.
RNA (0.5 mg) was converted to cDNA with Superscript III enzyme
(Invitrogen, Chicago, IL) and Q-PCR performed with iQ SYBR-
Green Supermix (BioRad, Hercules CA) using primers in Table
S2, in an MJ Research Chromo4 thermocycler. For primer
sequences and conditions see Table S2.
Immunostaining
Cells (2610
4/ml) were seeded on glass coverslips, allowed to
attach, AR was induced and activated. At indicated time points
the cells were fixed 10 min in methanol (220 C). All subsequent
steps were done at room temperature (RT). The coverslips were
washed with PBS, incubated 30 min in blocking solution (PBS, 2%
Donkey serum) and 1 hr in blocking solution with primary
antibodies. The slides were washed in PBS and incubated 30 min
with secondary antibodies conjugated with respective fluorescent
marker (Table S1) and washed with PBS. To counterstain nuclei,
Hoechst reagent was added in the last PBS wash. The slides were
mounted in Fluoromount G (Southern Biotech, Birmingham, AL)
and the staining evaluated by epi-fluorescent microscopy (Nikon
Diaphot 2000, MetaMorph software).
Detection of reactive oxygen species
ROS levels were assessed by Dihydroethidium (DHE) fluores-
cence (Sigma-Aldrich, St. Louis, MO). PCa cells were grown on
coverslips. DHE was added for the last 30 min of treatment to
10 mM final concentration. The cells were washed in PBS, fixed in
1.6% PFA and fluorescence was evaluated by epi-fluorescent
microscope (Nikon Diaphot 2000).
Chromatin immunoprecipitation (ChIP)
We used EZ-ChIP kit (Millipore, Billerica, MA) following
manufacturer’s protocol. The cells (,10
7/condition) were cross-
linked with formaldehyde (added to the medium to final 1%),
harvested and lysed. The lysates were sonicated on wet ice to
obtain ,1 kb fragments (Branson Sonifier, ten 20-sec cycles, 30%
power, 40 sec rest periods), sheared DNA precipitated with AR
antibody (PG-21, 1:500, Millipore). For each sample pull-down
with IgG was run as a negative control. DNA-protein complexes
were isolated on Protein G agarose beads, cross-linking reversed,
protein digested with proteinase K. DNA was purified on spin
columns and real-time PCR performed with p21 promoter
primers (Table S2). Input genomic DNA was included for each
sample for normalization. Results were analyzed according to
assay instructions (BIOMOL GmbH, Hamburg) and reported as
fold change (FC) in occupancy calculated from the formula FC=2
(2DDCT [exp-con]) .
Chemokine detection
Chemokine detection was performed in conditioned media
(CM) after 3 and 5 days of treatment with Dox, alone or in
combination with DHT and Flutamide. CM was collected, cleared
of debris by cenrifugation. Samples were tested in triplicates using
Q-Plex
TM Human Cytokine/Chemokine array (Quansys Biosci-
ences, Logan, UT). The results were normalized per mg of protein
in respective cell lysates, to account for different proliferation rates.
Supporting Information
Figure S1 AR causes cellular senescence. (A) AR activation
did not cause increased apoptosis. PC3-AR cells were cultured in
Dox 2, 5 and 7 days with (&), or without (%) DHT. The cells
were harvested, and cell cycle distribution analyzed by flow
cytometry of propidium iodide stained cells. The percentage of
cells with decreased DNA content (Sub-G0 population) is reported.
(B) AR activation caused morphology consistent with senescence
or autophagy: PC3-AR cells were cultured on coverslips in Dox,
with or without DHT. Note flat, vacuolated morphology upon
DHT treatment. (C) AR activation failed to increase autophagy
marker, Beclin (BCN-1). PC3-AR cells cultured in Dox, with DHT
or without DHT for 1, 3 and 5 days and BCN-1 expression
evaluated by Western blot. * indicates non-specific band. (D–E)
LNCaP cells mount senescence response to DHT. (D) Represen-
tative images of LNCaP cells cultured for 3 days with DHT or
control EtOH. Senescence was measured using SA-bGal assay.
Note increased bGal positivity upon AR activation. (E) Senescent
cells were counted on the digital images of 5 random fields using
Image Tool 3.00 software (UTHSCSA); means of three indepen-
dent experiments with S.D.M. are shown. (F) AR-positive
senescent cells fail to recover. PC3-AR cells were grown in
testosterone-free maintenance media (control, C), or treated with
Dox/DHT (T, R). After 5 days the cells were treated with Dox/
DHT for additional 3 and 6 days (T, treatment) or transferred in
testosterone-free maintenance media for the same time period (R,
recovery). Senescence was measured as % of b-Gal positive cells.
(PDF)
Figure S2 AR activation halts tumor growth. (A, B) Male
nude mice were injected as in experiment shown in Fig. 2, with
10
6 PC3-V (vector control, A), or PC3-AR cells (B). Dox was
administered in drinking water; Flutamide (Fl) was given in
subcutaneous pellets, as above. Sham pellets were used as control.
The arrows indicate the beginning of Dox treatment. Note
decreased volume of the PC3-AR tumors in Dox/DHT-treated
group and reversal by Fl. (C, D) To test the effect of testosterone
on AR-positive LNCaP tumors castrated male mice are tradition-
ally used. The use of ectopic DHT precluded chemical castration.
Surgical castration of 20–30 male mice is a technically challenging
and lengthy procedure. We therefore used female nude mice,
which lack testes and therefore the bulk of circulating and tissue
androgens. LNCaP cells in Matrigel (2610
6 cells/0.1 ml/site)
were injected subcutaneously in the flanks (10 mice per treatment
group). Mice were given subcutaneous pellets containing DHT or
sham pellets (control). Tumors were measured every 3 days. The
arrow indicates the beginning of DHT treatment (pellet implan-
tation). Note the lower tumor volume in the DHT-treated group
(P,0.002). (E) Senescence was measured in snap-frozen tumor
sections using SA-bGal assay.
(PDF)
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merase or DNA damage response. (A) Telomerase in the
cells treated with Dox, or Dox/DHT for the indicated time
periods. In telomerase-positive samples 6-base ladders are seen,
starting at 50 bp, with a 36 bp internal control band (indicated
with arrowheads). Extra band between internal control and the
ladder indicates higher telomerase activity, but does not affect
overall detection. M50, M25, size control ladders. P, control for
primer dimers. +veC, positive control (immortalized RWPE-1
cells); Q-veC, quantitative control. (B) Average telomere length of
the telomeres in the samples: PC3 wt AR (dox, dox/dht, dox/dht/
flu, NT): 2.6 kbp; PC3: 3.2 kbp; Control DNA: 8.6 kbp. Lane1-
PC3 wtAR dox, lane2-PC3 wtAR dox/dht, lane3- PC3 wtAR
dox/dht/flu, lane4- PC3 wtAR untreated, lane5-PC3, lane6-
Control DNA (C–D) DNA damage assessment. RWPE-AR and
PC3-AR cells were grown on coverslips and treated 24 hours as
indicated, fixed and stained for phosphorylated histone cH2-AX
(C), to assess DNA damage. The extent of DNA damage was
quantified as the average number of cH2-AX positive foci per
nucleus in at least 300 cells (D). While PC3-AR tumor cells
predictably showed higher extent of DNA damage compared to
the normal RWPE-1 cells, the moderate differences between
DHT-treated and control cells were not statistically significant (P
value 0.3 and 0.4 for RWPE and PC3 cells, respectively).
(PDF)
Figure S4 Senescence-associated proteins in DHT-treat-
ed PCa cells. (A) p16 levels in PCa cells were found below
detection (measured by Western blot). PC3-AR cells were treated
as indicated and western blot of total cell lysates probed with p16
antibodies. (B, C) LNCaP cells were treated with DHT (D) or
DHT/Flutamide (DF) for 3 days. C indicates untreated control
(0.1% EtOH). Total (T) or nuclear (N) cell extracts were isolated.
Nuclear extracts were probed for AR and TATA binding protein
(TBP), to assess loading; total extracts were probed for p53 and
tubulin. (D) PC3-AR cells were treated with Dox and DOX/
DHT, where indicated. Phospho-Rb and Cyclin D1 were assessed
by Western blot. Note the difference between proteins in the
regulation patterns. (D) PC3-AR cells were treated for up to 5days
with Dox, DHT and flutamide at indicated combinations and Bcl-
2 was measured by Western blot. Note decreased Bcl-2 expression
in the presence of DHT and the reversal of the effect by flutamide.
(PDF)
Figure S5 Regulation of cytokine secretion by AR. PC3-
AR cells were treated with Dox (D) in the presence of DHT (DD)
or DHT and Flutamide (DDF) and conditioned media collected
after 3 and 5 days. Cytokines were measured in triplicate using
multiplex ELISA assay. Only the factors whose expression is
changed in the presence of DHT are shown. Statistical significance
was calculated by one-way analysis of variance (ANOVA). *
indicates P,0.03 and ** P,0.003, respectively.
(PDF)
Table S1 Antibodies used in the study.
(PDF)
Table S2 PCR primers/conditions used in this study.
(PDF)
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